FGFR-4 antibody | knockout validation | Santa Cruz sc-136988

This is a knockout-validated antibody summary, based on the publication "Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

FGFR-4 antibody | knockout validation | Santa Cruz sc-136988 figure 1
Figure 1. Western blot analysis of Rh4-FR4wt (WT) and Rh4-FR4ko clone 8 (KO) were performed with antibodies against FGFR1, 2 and 4. From [1].
Antibody information

Mouse monoclonal IgG1 κ

Company: Santa Cruz

Antibody: FGFR-4

Catalog number: sc-136988

Summary: Mouse monoclonal antibody against amino acids 25-145 of human FGFR-4. Recommended for detection of FGFR-4 of mouse, rat and human origin by western blot, immunoprecipitation, immunofluorescence, immunohistochemistry (paraffin) and ELISA.

Validation Method

Western blot

Sample

WT and FGFR4-KO Rh4 cells.

Blocking agent

5% milk/TBST for 1 h at room temperature.

Primary incubation

1:1,000 dilution and incubated overnight at 4 °C

Secondary incubation

1:10,000 dilution HRP-conjugated anti-mouse IgG (#7076, Cell Signaling Technology, BioConcept, Allschwil, Switzerland) in blocking buffer for 1 h at room temperature.

Detection

Chemiluminescence was detected after incubation with AmershamTM ECLTM detection reagent (GE Healthcare, Opfikon, Switzerland) or SuperSignalTM West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, Illkirch, France) in a ChemiDocTM Touch Imaging System (BioRad, Cressier, Switzerland).

References
  1. Alijaj N, Moutel S, Gouveia Z, Gray M, Roveri M, Dzhumashev D, et al. Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma. Cancers (Basel). 2020;12: pubmed publisher